New York State Department Of Health Grants Lab Permit To Genetic Technologies Ltd. (GENE)

Sep. 03, 2013 3:50 PM ETGENE
MissionIR profile picture
MissionIR's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Small cap

Contributor Since 2010

We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value. View our website at MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit

Genetic Technologies announced this week that it has received its Clinical Laboratory Permit from the New York State Department of Health.

In late July, the DoH Clinical Laboratory Evaluation Program inspected the company's Melbourne laboratories; following the two-day audit, the company received a Laboratory Evaluation Report with "no significant deficiencies," allowing for the immediate issue of the permit.

This permit allows Genetic Technologies to meet requests received from New York physicians to provide the BREVAGen™ test to their patients and completes the out-of-state licensures that allows the company to provide testing services to all 50 U.S. states.

Having New York State as part of its territory will augment the current market adoption, which the company notes is delivering significant increases in the number of test samples provided to the laboratory during the current quarter to date.

"This is a wonderful endorsement of the quality of our laboratory systems and the validation package provided by our highly qualified staff," said Alison Mew, Genetic Technologies' CEO. "Importantly, it also allows women across the United States access to BREVAGen™ to deliver comprehensive breast health care."

For more information, visit

Please see disclaimer on the MissionIR website

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.